home > ebr > spring 2014 > human impact
European Biopharmaceutical Review

Human Impact

EBR: Can you give an overview of your company’s work on human proteins?

Stefan Wietek: Founded in 1983, Octapharma is now the world’s largest privately owned plasma manufacturer. It markets human plasma-derived proteins, the first of which was Octavi, a purified factor VIII that is required for blood clotting. The innovative solvent/ detergent (SD) treatment process we introduced has set the gold standard in the production of plasma-derived products. In 2013, we submitted for licence approval in Europe, Canada and Australia for our first recombinant human protein.

Which patient groups benefit from such products?

Our portfolio focuses on immunoglobulins to treat patients with primary and secondary immune disorders and prevent rhesus incompatibility in pregnancies; coagulation factors to treat patients with bleeding disorders; and plasma and plasma proteins used to restore coagulation function and prevent shock.

What are the challenges of developing human proteins?

Collecting sufficient amounts of human plasma from healthy donors is an important task. To produce pharmaceuticals from a biological substance like blood plasma is challenging because the raw material is not standardised. With the patient in mind, stringent quality processes – from blood donation through to robust manufacturing – are vital.

How does the newly trialled Heidelberg Assay Panel (HAP) test aim to help those with relapsing multiple sclerosis?

The HAP test is expected to have the potential to predict responders to intravenous immunoglobulin treatment and to distinguish them from non-responders. In this way, it may be possible to only treat patients who will benefit from treatment and save unnecessary costs for healthcare systems. The test is based on a single small blood sample, and assesses a combination of genomic and functional immune parameters. With this HAP test, Octapharma makes its first steps into the field of personalised medicine for patients suffering from this debilitating condition.

Are there any other areas of R&D currently in the pipeline?

The underlying principle of Octapharma’s R&D is the development of therapies to treat diseases within our therapeutic areas. These therapies are based on human proteins either purified from human plasma or produced by recombinant technologies applied to human cell lines. Other innovations under development include a fully pharmaceutically licensed, SD-treated, freeze-dried, non-blood-type-specific plasma in bags; a new fibrinogen product; and a human granulocyte colony-stimulating factor product.

What motivates you?

The plasma industry develops life-saving treatments that significantly enhance the quality of life for patients. Working in a truly international, fast-growing company with highly motivated people, short reporting lines and fast decisionmaking is highly motivating for me.

How do you think the industry will change over the next five years?

Supply of enough plasma will continue to be an issue; in an attempt to address this, most manufacturers are increasing their plasma collection and manufacturing capacities to cope with increasing demands. Our fundamental principle of improving patient care means we are constantly developing our portfolio to meet the growing and changing global demand.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Stefan Wietek is Head of Corporate Medical and Scientific Affairs at Octapharma and has 12 years of experience in the plasma industry. With a PhD in Molecular Biology, Stefan worked for Baxter’s Medical Affairs Europe department in 2002, before joining Octapharma three years later.
Stefan Wietek
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Industrial Security in the Pharmaceutical Sector


As an attractive target for cyber attacks, pharmaceutical companies need to understand cyber security, assess weak points and implement the appropriate security measures. This white paper describes some of the most effective industrial security tools pharmaceutical companies have at their disposal in the era of Industry 4.0.
More info >>

Industry Events



SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement